Latest
By Staff Report / Monday, September 14th, 2015 / Latest news, Tri-County Public Companies / Comments Off on Amgen licenses cancer drug to NatPharma
Amgen has licensed an experimental cancer drug to a Chicago biotech company founded and controlled by billionaire Patrick Soon-Shiong. NatPharma LLC is licensing the rights to AMG 337 from Thousand Oaks-based Amgen to develop and sell AMG 337. The drug is an experimental, phase-two cancer treatment. The licensing agreement is the second between Amgen and Read More →
Read More →
Latest
By Philip Joens / Friday, September 4th, 2015 / East Ventura County, Latest news, Top Stories / Comments Off on Lawmakers push ‘Make it in America’ bills to increase manufacturing jobs
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →
Latest
By Staff Report / Thursday, August 27th, 2015 / Latest news, Tri-County Public Companies / Comments Off on Amgen’s cholesterol-lowering drug Repatha gets U.S. approval
Thousand Oaks-based biotech giant Amgen won U.S. approval for its powerful cholesterol-lowering drug Repatha for certain patients, making it the second in a new class of treatments to come to market, Bloomberg News reported Aug. 27. The Food and Drug Administration cleared Repatha for people with hard-to-treat levels of bad cholesterol, according to a statement Read More →
Read More →
Latest
By Staff Report / Tuesday, August 18th, 2015 / Latest news, Technology, Top Stories, Tri-County Public Companies / Comments Off on Amgen agrees to pay $71 million over false marketing of 2 drugs
Thousand Oaks-based Amgen agreed to pay $71 million in a settlement with California, 47 other states and the District of Columbia because the biotech giant unlawfully promoted two drugs. According to a news release Aug. 18 from California Attorney General Kamala Harris, Amgen unlawfully promoted biologic medications Enbrel and Aranesp by “promoting Aranesp for dosing Read More →
Read More →
Latest
By Staff Report / Thursday, July 30th, 2015 / Latest news, Technology, Top Stories, Tri-County Public Companies / Comments Off on Amgen second-quarter profit beats analysts’ estimates
Thousand Oaks-based Amgen Inc. posted second-quarter profit that topped analysts’ estimates, driven by higher sales and lower operating expenses. The biotech also raised its revenue and earnings forecast for the year. Profit excluding one-time items rose to $2.57 a share, while analysts had predicted $2.43 on average. Revenue increased 3.7 percent to $5.37 billion, the Read More →
Read More →
